CELL-FREE secretome therapy restored hair growth in preclinical androgenic alopecia models by protecting papilla cells.
How the Hair Loss Therapy Works
Hair loss, particularly androgenic alopecia, remains difficult to treat because testosterone-driven apoptosis and impaired dermal papilla (DP) cell function disrupt the epithelial-mesenchymal signaling needed for follicle regeneration. In this study, researchers developed a cell-free regenerative therapy using the secretome of human fetal cartilage progenitor cells (ShFCPC). The therapy was enriched with extracellular matrix (ECM) proteins and bioactive factors linked to tissue remodeling, cell adhesion, and survival.
Proteomic analysis identified biomolecules associated with cell survival, adhesion, and tissue remodeling, supporting the rationale for using this secretome as a regenerative hair loss therapy rather than a conventional symptomatic approach.
Preclinical Evidence for Hair Loss Regeneration
In vitro, ShFCPC significantly improved DP cell viability, proliferation, and migration, particularly under testosterone-induced apoptotic stress. The treatment also restored β-catenin signaling and integrin-mediated extracellular matrix interactions, both of which are central to follicular regeneration.
The effect extended into a co-culture model, where ShFCPC promoted the formation of hair follicle germs (HFGs) and improved trichogenic marker expression and cellular organization. These findings suggest that the therapy may help recover the hair-inductive function of dermal papilla cells that is typically lost during hair loss progression.
What the Animal Data Showed
The most striking findings came from the in vivo models. ShFCPC-treated HFGs regenerated functional hair follicles in nude mice and reversed testosterone-induced hair loss in rats. Hair regrowth reached 94.9% coverage in treated animals versus 44.7% in controls. The treatment also improved follicle architecture, including sebaceous glands, dermal papillae, and hair shafts.
Investigators further reported significantly increased expression of β-catenin and CD34, two markers considered important for hair follicle regeneration. No toxicity was observed in treated animals, supporting the safety profile of this cell-free hair loss therapy at the preclinical stage.
Taken together, the findings position ShFCPC as a potential disease-modifying approach for hair loss, with effects on apoptosis, follicular signaling, and regenerative capacity rather than temporary cosmetic support alone.
Reference
Tran N-T et al. A novel cell-free regenerative therapy for hair loss: human fetal cartilage progenitor cell secretome. Biomaterials. 2026;325:123627.
Featured Image: LIGHTFIELD STUDIOS on Adobe Stock.
